Form 4: ARCH Venture Partners Boosts Neumora Therapeutics Stake

ARCH Venture Partners XII, LLC and affiliated entities plan to acquire 1.9 million shares of Neumora Therapeutics common stock for $2.61 per share, increasing their beneficial ownership.

Summary

• ARCH Venture Partners XII, LLC, along with several affiliated ARCH Venture Funds and managing directors, reported a planned acquisition of Neumora Therapeutics, Inc. common stock.
• The transaction involves the acquisition of 1,915,700 shares of common stock at a price of $2.61 per share.
• The transaction date is set for October 27, 2025.
• Following this transaction, ARCH Venture Fund XII, L.P. will beneficially own 6,046,907 shares.
• The collective beneficial ownership of Neumora Therapeutics common stock by all reporting ARCH entities and individuals will total 33,847,838 shares.
• The reporting persons include ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., and managing directors Keith Crandell, Steven Gillis, Robert Nelsen, and Clinton Bybee.
• These reporting persons are identified as both Directors and 10% Owners of Neumora Therapeutics, Inc.

Sentiment

Score: 8

Explanation: The planned significant insider purchase by a major institutional investor and director group indicates strong confidence in the company's future, which is a highly positive signal for the market.

Positives

• A significant planned purchase of 1,915,700 shares by a major institutional investor and 10% owner, ARCH Venture Partners, signals strong confidence in Neumora Therapeutics' future prospects.
• The acquisition price of $2.61 per share indicates a specific valuation at which the insider is willing to increase their stake.
• The collective beneficial ownership of 33,847,838 shares by ARCH entities demonstrates a substantial, long-term commitment to the company.

Future Outlook

The planned acquisition by a significant institutional investor and director group suggests a positive long-term outlook for Neumora Therapeutics, as insiders are increasing their stake at a specific valuation.

Industry Context

This insider buying activity by a prominent venture capital firm like ARCH Venture Partners, which specializes in life sciences, could be interpreted as a positive signal for Neumora Therapeutics within the biotechnology sector, potentially indicating confidence in the company's pipeline or strategic direction.

Related Party Transactions

• The reported transaction is a related party transaction, as ARCH Venture Partners XII, LLC and its affiliated entities are 10% owners and have directors on the board of Neumora Therapeutics, Inc.

Stakeholder Impact

• Shareholders: The planned insider buying by a major institutional investor and director group could instill greater confidence in existing shareholders and attract new investors, potentially leading to positive share price movement.
• Company Management: The increased stake by a significant investor reinforces alignment between management and a key shareholder, potentially supporting long-term strategic decisions.

Key Dates

Recommendation

A significant planned purchase by ARCH Venture Partners, a prominent institutional investor and 10% owner with board representation, signals high conviction in Neumora Therapeutics' valuation and future prospects. Such a substantial insider commitment, especially at a specific price point, often precedes positive developments or reflects deep confidence in the company's long-term strategy and potential, making it a strong buy signal for seasoned investors.

Keywords

Neumora Therapeutics, NMRA, ARCH Venture Partners, Insider Buying, Stock Purchase, Beneficial Ownership, Biotechnology, Venture Capital, SEC Form 4